MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Amneal Pharmaceuticals Cash Conversion Cycle 2011-2026 | AMRX
Annual Cash Conversion Cycle Amneal Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123 | 129 | 130 | 170 | 198 | 222 | 256 | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 256 | 123 | 176 |
Quarterly Cash Conversion Cycle Amneal Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 67.1 | 84.5 | 80 | 77.7 | 77.9 | - | - | 96.7 | 196 | - | 250 | 233 | 233 | - | 255 | 245 | 234 | - | 239 | 266 | 226 | 139 | 276 | 254 | 218 | 88.3 | 198 | 251 | 235 | - | 289 | 133 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 289 | 67.1 | 190 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Adagene
ADAG
|
53.8 | $ 2.62 | 28.82 % | $ 147 M |  China |
 |
GlaxoSmithKline plc
GSK
|
0.02 | $ 48.98 | 0.68 % | $ 173 B |  Britain |
 |
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K |  USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
Grifols, S.A.
GRFS
|
0.000171 | $ 9.25 | 1.49 % | $ 6.83 B |  Spain |
 |
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | USA |
 |
Galapagos NV
GLPG
|
67.1 | $ 34.61 | 0.61 % | $ 2.69 B |  Belgium |
 |
Zoetis
ZTS
|
322 | $ 123.99 | -0.31 % | $ 56.3 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M |  Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
8.75 | $ 67.49 | -3.02 % | $ 9.03 B | USA |
 |
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-8.96 K | - | -10.17 % | $ 12.2 K | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
25 | - | -15.15 % | $ 60.3 M | Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
166 | $ 25.92 | -0.86 % | $ 1.26 B | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
-1.55 K | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-2.85 K | - | -11.43 % | $ 502 K | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M |  Israel |
 |
Aytu BioScience
AYTU
|
174 | $ 2.66 | -1.85 % | $ 16.7 M | USA |
 |
AstraZeneca PLC
AZN
|
-58 | $ 92.87 | 1.28 % | $ 96.9 B | Britain |
 |
Arena Pharmaceuticals
ARNA
|
946 | - | -6.81 % | $ 3.04 B | USA |
 |
Brickell Biotech
BBI
|
149 | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
49.5 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biogen
BIIB
|
387 | $ 171.89 | -1.1 % | $ 25 B | USA |